- Home
- KREF vs AUTL Comparison
KREF vs AUTL Comparison
Compare KREF & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KREF | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.8M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | KREF | AUTL |
|---|---|---|
| Price | $6.65 | $1.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $9.58 | $8.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $545.92 | $84.74 |
| Revenue Next Year | N/A | $65.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $5.87 | $1.15 |
| 52 Week High | $9.98 | $2.70 |
Technical Indicators
Market Signals| Indicator | KREF | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 53.24 |
| Support Level | $6.64 | $1.45 |
| Resistance Level | $7.50 | $1.52 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 98.74 | 75.31 |
Price Performance
Historical ComparisonAbout KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.